Assesses cognitive impairment risk in older adults with type 2 diabetes, suggesting potential implications for treatment options.
To assess whether glucagon-like peptide 1 (GLP-1) analogues change the risk of developing cognitive impairment among older adults with type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Thorman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: